{"id":68513,"date":"2026-03-09T12:55:59","date_gmt":"2026-03-09T17:55:59","guid":{"rendered":"https:\/\/news2shorts.com\/index.php\/2026\/03\/09\/trumps-rx-plan-promises-savings-but-economists-see-a-hidden-trade-off\/"},"modified":"2026-03-09T12:55:59","modified_gmt":"2026-03-09T17:55:59","slug":"trumps-rx-plan-promises-savings-but-economists-see-a-hidden-trade-off","status":"publish","type":"post","link":"https:\/\/news2shorts.com\/index.php\/2026\/03\/09\/trumps-rx-plan-promises-savings-but-economists-see-a-hidden-trade-off\/","title":{"rendered":"Trump’s Rx plan promises savings, but economists see a hidden trade-off"},"content":{"rendered":"

President Donald Trump’s<\/a> latest push to slash prescription drug prices promises relief at the pharmacy counter, but behind the headline savings lie trade-offs that could reshape how drugs are developed, priced and delivered in the United States.<\/p>\n

To deliver on that promise, the administration has rolled out TrumpRx, a federal price-comparison platform aimed at lowering out-of-pocket costs. The effort unfolds against the backdrop of the midterm election<\/u><\/a> cycle, where rising healthcare costs remain a central concern for voters and a defining campaign issue.<\/p>\n

The political appeal is clear, but experts warn the economics are messier. Economists point to a basic trade-off: lower prices today can shape how and whether new drugs are developed tomorrow.<\/p>\n

\u2018PUNCH IN THE GUT\u2019: WEST VIRGINIA WOMAN TELLS CONGRESS HER OBAMACARE PREMIUM JUMPED 323%<\/strong><\/a><\/p>\n

“When drug prices are capped or negotiated down, companies anticipate lower returns, reducing investment in drug research<\/a> and development,” said Olivia Mitchell, a professor of business economics and public policy at the Wharton School.<\/p>\n

“Economic evidence shows that lower prices depress incentives to develop new drugs,” she added.\u00a0<\/p>\n

“In the short term, patients and payers can see meaningful savings through lower prices and out-of-pocket costs, but in the longer term, there is more risk of fewer or slower-arriving new medicines, especially in areas most exposed to price controls.”<\/p>\n

TRUMP SECURES AGREEMENTS WITH MAJOR DRUGMAKERS TO LOWER MEDICAID PRESCRIPTION COSTS FOR AMERICANS<\/u><\/strong><\/a><\/p>\n

Michael Baker, director of healthcare policy at the American Action Forum, said government price setting does not eliminate costs so much as redistribute them.<\/p>\n

“At the most basic level, government price setting only limits what patients pay for a drug \u2014 usually reflected in an out-of-pocket or co-insurance payment,” Baker said. “This does nothing to address the overall cost of the drug, which someone still has to pay, nor does it lower the cost associated with development.”<\/p>\n

As a result, he said, those costs could reemerge through tighter health coverage rules, fewer treatment options or reduced future innovation.<\/p>\n

Supporters of the administration counter that the policy does not amount to strict government price caps. Instead, they describe it as a negotiated arrangement.<\/p>\n

HOW TO USE TRUMP RX TO FIND CHEAPER CASH PRICES ON MEDICATIONS<\/strong><\/a><\/p>\n

Ed Haislmaier of the Heritage Foundation said companies appear to be lowering prices in exchange for expanded market access or other relief, a structure he argues avoids the most disruptive effects of traditional price controls.<\/p>\n

“In such cases, companies are likely calculating that revenue losses from lower prices will be offset by revenue gains from more sales,” Haislmaier told Fox News Digital.\u00a0<\/p>\n

“The kind of government price controls that are most damaging to innovation are ones that limit the initial price a company can charge for a new product. That is the situation in some countries, but fortunately not yet in the United States,” he added.<\/p>\n

For patients squeezed by rising costs, the promise of immediate savings is hard to dismiss.\u00a0<\/p>\n

But economists say the long run question is whether the system can deliver cheaper drugs without dulling the incentives that produce the next generation of treatments \u2014 <\/strong>an issue both parties are likely to keep pressing as health costs<\/a> stay front and center.<\/p>\n","protected":false},"excerpt":{"rendered":"

President Donald Trump’s latest push to slash prescription drug prices promises relief at the pharmacy counter, but behind the headline savings lie trade-offs that could reshape how drugs are developed, priced and delivered in the United States. To deliver on that promise, the administration has rolled out TrumpRx, a federal price-comparison platform aimed at lowering …